About Larimar Therapeutics, Inc.
https://www.larimartx.comLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
CEO
Carole S. Ben-Maimon
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-05-29 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Baird
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:30.61M
Value:$104.37M
RA CAPITAL MANAGEMENT, L.P.
Shares:6.05M
Value:$20.61M
BLUE OWL CAPITAL HOLDINGS LP
Shares:5.85M
Value:$19.96M
Summary
Showing Top 3 of 145
About Larimar Therapeutics, Inc.
https://www.larimartx.comLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $49.5M ▲ | $-47.71M ▼ | 0% | $-0.61 ▼ | $-47.62M ▼ |
| Q2-2025 | $0 | $27.79M ▼ | $-26.18M ▲ | 0% | $-0.41 ▲ | $-27.7M ▲ |
| Q1-2025 | $0 | $31.19M ▼ | $-29.28M ▼ | 0% | $-0.46 ▼ | $-31.1M ▲ |
| Q4-2024 | $0 | $31.29M ▲ | $-28.82M ▼ | 0% | $-0.45 ▼ | $-31.22M ▼ |
| Q3-2024 | $0 | $18.26M | $-15.5M | 0% | $-0.24 | $-18.19M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $175.44M ▲ | $187.35M ▲ | $48.31M ▲ | $139.04M ▲ |
| Q2-2025 | $138.52M ▼ | $149.99M ▼ | $30.13M ▲ | $119.85M ▼ |
| Q1-2025 | $157.53M ▼ | $170.18M ▼ | $25.9M ▼ | $144.27M ▼ |
| Q4-2024 | $183.45M ▼ | $200.22M ▼ | $28.41M ▲ | $171.81M ▼ |
| Q3-2024 | $203.71M | $219.02M | $20.62M | $198.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-47.71M ▼ | $-28.75M ▼ | $33.02M ▲ | $65.29M ▲ | $69.55M ▲ | $-28.78M ▼ |
| Q2-2025 | $-26.18M ▲ | $-19.38M ▲ | $18.84M ▲ | $0 | $-539K ▲ | $-19.4M ▲ |
| Q1-2025 | $-29.28M ▼ | $-26.54M ▼ | $14.45M ▼ | $0 ▼ | $-12.09M ▼ | $-26.59M ▼ |
| Q4-2024 | $-28.82M ▼ | $-21.82M ▲ | $19.2M ▼ | $36K ▲ | $-2.58M ▼ | $-21.99M ▲ |
| Q3-2024 | $-15.5M | $-24.55M | $27.27M | $30K | $2.76M | $-24.61M |
CEO
Carole S. Ben-Maimon
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-05-29 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 53
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Oppenheimer
Outperform
Baird
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:30.61M
Value:$104.37M
RA CAPITAL MANAGEMENT, L.P.
Shares:6.05M
Value:$20.61M
BLUE OWL CAPITAL HOLDINGS LP
Shares:5.85M
Value:$19.96M
Summary
Showing Top 3 of 145